+

NO20065757L - Purinderivater - Google Patents

Purinderivater

Info

Publication number
NO20065757L
NO20065757L NO20065757A NO20065757A NO20065757L NO 20065757 L NO20065757 L NO 20065757L NO 20065757 A NO20065757 A NO 20065757A NO 20065757 A NO20065757 A NO 20065757A NO 20065757 L NO20065757 L NO 20065757L
Authority
NO
Norway
Prior art keywords
purine derivatives
formula
adenosine
solvates
agonists
Prior art date
Application number
NO20065757A
Other languages
English (en)
Norwegian (no)
Inventor
Derek Norman Evans
Philip Blatcher
Richard Peter Charles Cousins
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411563A external-priority patent/GB0411563D0/en
Priority claimed from GB0509521A external-priority patent/GB0509521D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20065757L publication Critical patent/NO20065757L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20065757A 2004-05-24 2006-12-13 Purinderivater NO20065757L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411563A GB0411563D0 (en) 2004-05-24 2004-05-24 Compounds
GB0509521A GB0509521D0 (en) 2005-05-10 2005-05-10 Compounds
PCT/EP2005/005651 WO2005116037A1 (fr) 2004-05-24 2005-05-23 Dérivé de purine

Publications (1)

Publication Number Publication Date
NO20065757L true NO20065757L (no) 2006-12-13

Family

ID=34968031

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065757A NO20065757L (no) 2004-05-24 2006-12-13 Purinderivater

Country Status (16)

Country Link
US (1) US7737126B2 (fr)
EP (1) EP1756120B1 (fr)
JP (1) JP5007225B2 (fr)
AR (1) AR049384A1 (fr)
AT (1) ATE556080T1 (fr)
AU (1) AU2005247601A1 (fr)
BR (1) BRPI0511424A (fr)
CA (1) CA2566863A1 (fr)
ES (1) ES2383604T3 (fr)
IL (1) IL179009A0 (fr)
MA (1) MA28611B1 (fr)
MX (1) MXPA06013627A (fr)
NO (1) NO20065757L (fr)
PE (1) PE20060272A1 (fr)
RU (1) RU2006141276A (fr)
WO (1) WO2005116037A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0523778D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel method
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
EP1953139A4 (fr) * 2005-11-25 2010-07-28 San Apro Ltd Procede pour produire un alkylfluorophosphate de sulfonium fluore
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP2013211B1 (fr) 2006-04-21 2012-03-14 Novartis AG Derives de purine utilises en tant que recepteurs agonist d'adenosin a2a
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
EP1903044A1 (fr) 2006-09-14 2008-03-26 Novartis AG Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
EP2084121A1 (fr) * 2006-11-10 2009-08-05 Novartis AG Dérivés de monoacétate de cyclopentène diol

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3796700A (en) 1970-06-30 1974-03-12 Takedo Chem Ind Ltd Adenosine derivatives and the production thereof
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (fr) 1972-04-10 1980-07-29 Francis E. Fischer Preparation d'adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
CA1239397A (fr) 1983-08-01 1988-07-19 James A. Bristol Adenosines substituee en position n.sup.6
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
ATE50777T1 (de) 1984-04-18 1990-03-15 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
CA1254888A (fr) 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicyclo-adenosines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003148A2 (fr) 1986-10-31 1988-05-05 Warner-Lambert Company Derives heteroaromatiques d'adenosine
AU8276187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
EP0277917A3 (fr) 1987-02-04 1990-03-28 Ciba-Geigy Ag Certains dérivés d'adénosine-5'-carboxamide
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
PT95628A (pt) 1989-10-19 1991-09-30 Searle & Co Metodo de tratamento de perturbacoes de mobilidade gastrointestinal com composto de adenosina
WO1991010671A1 (fr) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions et procedes servant a detecter et a moduler l'activite arn et l'expression des genes
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
ES2095960T3 (es) 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
CA2100863A1 (fr) 1991-01-23 1992-07-24 David A. Bullough Inhibiteurs de l'adenosine-kinase
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (fr) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives sulfo d'adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
JPH08506343A (ja) 1993-02-03 1996-07-09 ジェンシア・インコーポレイテッド リキソフラノシル誘導体を含むアデノシンキナーゼ阻害物質
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
EP0765308B1 (fr) 1994-06-15 2000-04-05 The Wellcome Foundation Limited Inhibiteurs d'enzymes
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
WO1996036729A1 (fr) 1995-05-18 1996-11-21 Coulter International Corp. Reactif d'analyse, procede de production et mode d'emploi_______
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5789589A (en) 1996-04-22 1998-08-04 Drug Innovation & Design, Inc. Guanine analog phosphates
WO1998001459A1 (fr) 1996-07-05 1998-01-15 Novo Nordisk A/S Nouveaux derives de n-alcoxyadenine inhibant la cytokine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (fr) 1996-10-14 1998-04-23 Novo Nordisk A/S Nouveaux derives d'adenosine a action therapeutique
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
US6710051B1 (en) 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
WO1999047505A1 (fr) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de pde iii/iv a base de phtalazinones
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
WO1999067265A1 (fr) 1998-06-23 1999-12-29 Glaxo Group Limited Derives du 2-(purin-9-yl)-tetrahydrofuran-3,4 diol
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
MY121142A (en) 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
DE60022366T2 (de) 1999-07-02 2006-06-14 Eisai Co Ltd Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6803457B1 (en) 1999-09-30 2004-10-12 Pfizer, Inc. Compounds for the treatment of ischemia
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AU2700201A (en) 2000-01-31 2001-08-14 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
IL150486A0 (en) 2000-01-31 2002-12-01 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6710086B1 (en) 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0016002D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
WO2002026722A1 (fr) 2000-09-29 2002-04-04 Glaxo Group Limited Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires
AU2002210761A1 (en) 2000-11-03 2002-05-15 Glaxo Group Limited Method of determining susceptibility to diseases
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
ATE292973T1 (de) 2001-01-16 2005-04-15 Can Fite Biopharma Ltd Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
ES2239203T3 (es) 2001-01-31 2005-09-16 Pfizer Products Inc. Derivados nicotinamida y sus mimeticos como inhibidores de isozimas pde4.
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0104555D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7144908B2 (en) 2001-03-08 2006-12-05 Glaxo Group Limited Agonists of beta-adrenoceptors
AU2002238748A1 (en) 2001-03-12 2002-09-24 Glaxo Group Limited Pharmaceutical aerosol formulation
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
DK1373259T3 (da) 2001-03-30 2005-03-29 Pfizer Prod Inc Pyridazinonaldosereduktaseinhibitorer
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US6903109B2 (en) 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
GB0120124D0 (en) 2001-05-04 2001-10-10 Aventis Pharm Prod Inc Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
AP2003002911A0 (en) 2001-05-25 2003-12-31 Pfizer An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
US7262176B2 (en) 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
KR100912324B1 (ko) 2001-09-14 2009-08-14 글락소 그룹 리미티드 호흡기 질환 치료용 펜에탄올아민 유도체
SG176313A1 (en) 2001-10-01 2011-12-29 Univ Virginia Patent Found 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
CN1578665A (zh) 2001-10-31 2005-02-09 默克专利股份公司 4型磷酸二脂酶抑制剂及其应用
CA2465364A1 (fr) 2001-11-02 2003-05-15 Aventis Pharmaceuticals Inc. Composition pharmaceutique comprenant un agoniste d'adenosine a1/a2 et un inhibiteur d'echangeur sodium-hydrogene
CN1585641A (zh) 2001-11-05 2005-02-23 默克专利有限公司 亚肼基－丙二腈化合物
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163991A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
DE60309829T2 (de) 2002-01-14 2007-09-13 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoidmimetika, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische formulierungen und ihre verwendungen
WO2003062256A1 (fr) 2002-01-17 2003-07-31 Ribapharm Inc. Analogues d'adenosine 2'-beta-modifiee-6-substituee et leur utilisation en tant qu'agents antiviraux
US6831093B2 (en) 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
JP2006502088A (ja) 2002-01-25 2006-01-19 マスカジエン・リミテツド Ａ３アデノシン受容体作動薬として有用な化合物
NZ534197A (en) 2002-02-11 2007-01-26 Pfizer Nicotinamide derivatives useful as PDE4 inhibitors
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JPWO2003077891A1 (ja) 2002-03-18 2005-07-14 アステラス製薬株式会社 吸入用粉末医薬組成物およびその製造方法
WO2003080053A1 (fr) 2002-03-18 2003-10-02 Schering Corporation Traitements combines pour maladies induites par la chimiokine
GB0206655D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
GB0206657D0 (en) 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
ES2298508T3 (es) 2002-03-26 2008-05-16 Boehringer Ingelheim Pharmaceuticals Inc. Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
US20040127510A1 (en) 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
AU2003222841A1 (en) 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
AU2003251303A1 (en) 2002-05-21 2003-12-12 Glaxo Group Limited Pharmaceutical products and methods of manufacture
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2518940T3 (es) 2002-07-08 2014-11-06 Pfizer Products Inc. Moduladores del receptor de glucocorticoides
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ES2337679T3 (es) 2002-07-18 2010-04-28 Bristol-Myers Squibb Company Composiciones y procedimientos que implican el sitio ii de los receptores nucleares de hormonas.
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
EP1532113B1 (fr) 2002-08-21 2008-08-06 Boehringer Ingelheim Pharmaceuticals Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2004084800A2 (fr) 2002-08-29 2004-10-07 Pfizer Products Inc. Proteines cardioprotectrices a mediation du recepteur a3, leurs methodes therapeutiques et diagnostiques d'utilisation
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
CA2535792A1 (fr) 2002-09-09 2004-03-18 Trigen Limited Sels d'acide boronique et leur utilisation dans le traitement de la thrombose
ATE449782T1 (de) 2002-09-09 2009-12-15 Cv Therapeutics Inc Adenosin a3 rezeptor agonisten
US7112572B2 (en) 2002-09-09 2006-09-26 Trigen Limited Multivalent metal salts of boronic acids
JP4516844B2 (ja) 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド 創傷の処置におけるラクトフェリン
BR0314392A (pt) 2002-09-16 2005-07-12 Glaxo Group Ltd Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação
US20050245588A1 (en) 2002-09-20 2005-11-03 Amjad Ali Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
US20040229780A1 (en) 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
AU2003270752A1 (en) 2002-09-27 2004-04-19 King Pharmaceuticals Research And Development, Inc. A method to demonstrate the efficacy of pharmacological stress agent
US20060100168A1 (en) 2002-09-30 2006-05-11 The Trustee Of Boston University Method of treating cancer using adenosine and its analogs
CN1720240B (zh) 2002-10-09 2010-10-27 先灵公司 作为cxc-和cc-趋化因子受体配体的噻二唑二氧化物和噻二唑氧化物
EP1407769A1 (fr) 2002-10-11 2004-04-14 Pfizer Limited Derivés d'indole comme beta-2 agonistes
US6844362B2 (en) 2002-10-11 2005-01-18 Pfizer Inc Indole derivatives useful for the treatment of diseases
KR20050047552A (ko) 2002-10-11 2005-05-20 화이자 인코포레이티드 베타-2 작용제로서의 인돌 유도체
WO2004037807A2 (fr) 2002-10-22 2004-05-06 Glaxo Group Limited Composes medicinaux
EP1578758A4 (fr) 2002-10-25 2009-09-30 Us Gov Health & Human Serv Nucleosides puriques
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
RU2332400C2 (ru) 2002-10-28 2008-08-27 Глаксо Груп Лимитед Производные фенэтаноламина для лечения респираторных заболеваний
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
WO2004050040A2 (fr) 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Composition pharmaceutique de 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine et utilisations
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
CA2512819A1 (fr) 2003-01-14 2004-07-29 Altana Pharma Ag Inhibiteurs de pde4 pour le traitement de neoplasmes de cellules lymphoides
US20040166574A1 (en) 2003-02-25 2004-08-26 Antonius John I. Microorganism
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
US20040258740A1 (en) 2003-04-10 2004-12-23 Nene Labs Transdermal delivery composition
MXPA05011225A (es) 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
EP1477167A1 (fr) 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
US7067541B2 (en) 2003-06-04 2006-06-27 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
DE602004011513T2 (de) 2003-06-04 2009-01-29 Pfizer Inc. 2-amino-pyridin-derivate als beta-2 adrenoreceptor agonisten
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004110454A1 (fr) 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. Composition de traitement ou de prevention de maladies necessitant l'administration d'un agoniste du recepteur a2a de l'adenosine
US6974862B2 (en) 2003-06-20 2005-12-13 Kensey Nash Corporation High density fibrous polymers suitable for implant
GB0317516D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
GB0317509D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) 2003-07-25 2006-11-07 Pfizer Inc. Compounds
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317472D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317471D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Novel compounds
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317498D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Compounds
GB0317951D0 (en) 2003-07-31 2003-09-03 Trigen Ltd Compounds
NZ545979A (en) 2003-09-18 2009-02-28 King Pharmaceuticals Res & Dev Novel adenosine A3 receptor agonists

Also Published As

Publication number Publication date
JP2008500378A (ja) 2008-01-10
IL179009A0 (en) 2007-03-08
BRPI0511424A (pt) 2007-12-11
EP1756120B1 (fr) 2012-05-02
MXPA06013627A (es) 2007-02-28
JP5007225B2 (ja) 2012-08-22
RU2006141276A (ru) 2008-06-27
AU2005247601A1 (en) 2005-12-08
WO2005116037A1 (fr) 2005-12-08
ES2383604T3 (es) 2012-06-22
CA2566863A1 (fr) 2005-12-08
US7737126B2 (en) 2010-06-15
MA28611B1 (fr) 2007-05-02
US20080132526A1 (en) 2008-06-05
EP1756120A1 (fr) 2007-02-28
AR049384A1 (es) 2006-07-26
ATE556080T1 (de) 2012-05-15
PE20060272A1 (es) 2006-05-22

Similar Documents

Publication Publication Date Title
NO20065757L (no) Purinderivater
NO20074050L (no) Purinderivater som fungerer som A2A-receptoragonister
NO20072122L (no) Purinderivater for anvendelse som adenosin A-2A-reseptoragonister
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20076450L (no) Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi
CU23497A3 (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
NO20064888L (no) Heterocykliske CGRP antagonister for behandling av migrene
NO20061254L (no) Farmasoytiske blandinger
BRPI0606870A2 (pt) composto de indol e uso do mesmo
NO20062489L (no) Heterocykliske anti-migrenemidler
NO20062648L (no) Calcitonin gen relaterte peptid reseptor antagonister
PT1252157E (pt) Carboxamidas de pirimidina uteis como inibidores de isozimas pde4
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20085257L (no) Purinonderivater som HM74a-agonister
WO2005021515A3 (fr) Inhibiteurs de la phosphodiesterase de type iv
EA200900472A1 (ru) Ингибиторы фосфодиэстеразы iv типа
BRPI0514289A (pt) compostos orgánicos
NO20080457L (no) Kjemiske forbindelser
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
NI200700039A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38.
ES2174756A1 (es) Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias.
MXPA05012772A (es) Derivados de benzotiazol y uso de los mismos en el tratamiento de enfermedades relacionadas con el receptor a2a de adenosina.
NO20064806L (no) Formamidderivater anvendelige som adenoceptor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载